StratDeck

Two stocks in Drug Manufacturers - General

Amgen vs Pfizer: profit, growth, debt and price compared

Pfizer is stronger on 4 of 7 figures: debt, price for its expected profit, dividend and analysts' view. Amgen is stronger on 3: profit margin, sales growth and price trend.

Figures as of 18 November 2026SEC EDGARYahoo Finance

Save both stocks to your watchlist and revisit their latest fundamentals.

Amgen and Pfizer side by side
AmgenAMGNPfizerPFE
Net marginStronger: 24.1%6.3%
Revenue growth, past yearStronger: +8.45%−0.43%
Debt to equity376.3%Stronger: 71.0%
Forward P/E17.7×Stronger: 9.5×
Dividend yield2.27%Stronger: 6.13%
AnalystsHold · 29Stronger: Buy · 26
From its 200-day averageStronger: +14.8%+6.1%

Share price over the past year

  • Amgen+29.0%
  • Pfizer+10.3%

18 Nov 202518 Nov 2026

Amgen or Pfizer: which is stronger?

  • AMGN

    Which is more profitable?

    Amgen keeps more of each sale as profit: 24.1% against 6.3%.

  • AMGN

    Which is growing its sales faster?

    Amgen is growing its sales faster: +8.45% over the past year, against −0.43%.

  • PFE

    Which has borrowed less?

    Pfizer has borrowed less: its debt is 71.0% of what its shareholders own, against 376.3% for Amgen.

  • PFE

    Which costs less for the profit it is expected to make?

    Pfizer costs less for the profit it is expected to make: 9.5× its forward earnings, against 17.7×.

  • PFE

    Which pays more in dividends?

    Pfizer pays more back in dividends for what a share costs: 6.13% a year, against 2.27%.

  • PFE

    Which do analysts rate higher?

    Analysts are warmer on Pfizer: Buy, against Hold for Amgen.

  • AMGN

    Which is in the stronger price trend?

    Amgen's price is in the stronger trend: 14.8% above its 200-day average, against 6.1% above.

What each company does

AMGNAmgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Reports results on 2 February 2027

PFEPfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Reports results on 2 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every US healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.